1-6 of 6
Anderson Ryan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B88: Mechanisms of resistance to the Hsp90 inhibitor ganetespib in triple negative breast cancer

Nuramalina H. Mumin, Sivan Bokobza, Fiona Cahill, Neele Drobnitzky, Yanyan Jiang, Luiza Madia Lourenco, Aoife Vaughan, Anika Weber, Anthony Kong, Anderson Ryan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B88.
https://doi.org/10.1158/1535-7163.TARG-15-B88
Published: 01 December 2015
View article titled, Abstract B88: Mechanisms of resistance to the Hsp90 inhibitor ganetespib in triple negative breast cancer
Journal Articles

Abstract A154: Preclinical investigation of gefitinib combined with radiation in EGFR-mutation positive non-small cell lung cancer.

Sivan Bokobza, Anika Weber, Aoife Devery, Anderson Ryan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A154.
https://doi.org/10.1158/1535-7163.TARG-11-A154
Published: 12 November 2011
View article titled, Abstract A154: Preclinical investigation of gefitinib combined with radiation in <em>EGFR</em>-mutation positive non-small cell lung cancer.
Journal Articles

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines

M. Pia Morelli, Amy M. Brown, Todd M. Pitts, John J. Tentler, Fortunato Ciardiello, Anderson Ryan, Juliane M. Jürgensmeier, S. Gail Eckhardt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (9): 2546–2558.
https://doi.org/10.1158/1535-7163.MCT-09-0380
Published: 17 September 2009
View article titled, Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines
Open the PDF for Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines in another window
Journal Articles

Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium

Paul Beaudry, Monique Nilsson, Matthew Rioth, Daniela Prox, David Poon, Lanwei Xu, Patrick Zweidler-Mckay, Anderson Ryan, Judah Folkman, Sandra Ryeom, John Heymach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (2): 418–424.
https://doi.org/10.1158/1535-7163.MCT-07-0568
Published: 15 February 2008
View article titled, Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium
Open the PDF for Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium in another window
Journal Articles

Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of paclitaxel in orthotopic human lung adenocarcinoma models

Kazuhisa Furutani, Ritsuko Komaki, Toshio Kuwai, Joerg Jacoby, Maria Korshunova, Baruch Erez, Anderson Ryan, Juliane Jurgensmeier, Roy Herbst, Michael O'Reilly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A25.
Published: 01 November 2007
View article titled, Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of paclitaxel in orthotopic human lung adenocarcinoma models
Journal Articles

Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of irinotecan in orthotopic human small cell lung cancer models

Roy Herbst, Kazuhisa Furutani, Ritsuko Komaki, Toshio Kuwai, Takeshi Isobe, Maria Korshunova, Baruch Erez, Anderson Ryan, Juliane Jurgensmeier, Michael O'Reilly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A26.
Published: 01 November 2007
View article titled, Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of irinotecan in orthotopic human small cell lung cancer models